Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).

被引：1
|
作者：
Weathers, Shiao-Pei S.
Kamiya-Matsuoka, Carlos
Harrison, Rebecca A.
Liu, Diane D.
Dervin, Shannon
Yun, Cindy
Loghin, Monica Elena
Penas-Prado, Marta
Majd, Nazanin
Yung, W. K. Alfred
O'Brien, Barbara Jane
De Groot, John Frederick
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2511
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. M. P.
    Beal, K.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Gavrilovic, I. T.
    Nolan, C.
    Hormigo, A.
    Lassman, A. B.
    Kaley, T. J.
    Mellinghoff, I. K.
    Grommes, C.
    Panageas, K.
    Reiner, A. S.
    Barradas, R.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [12] Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)
    Beal, K.
    Omuro, A.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Yamada, Y.
    Abrey, L. E.
    Gutin, P. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S129 - S129
  • [13] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. A.
    Beal, K.
    Karimi, S.
    Chan, T. A.
    Panageas, K.
    Nayak, L.
    Seko, B.
    DeAngelis, L. M.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [14] Combination of temozolomide (TMZ) and radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma multiforme (GBM): A randomized phase II study
    Athanassiou, H
    Synodinou, M
    Maragoudakis, E
    Paraskevaidis, M
    Verigos, C
    Misailidou, D
    Antonadou, D
    Sarris, G
    Beroukas, K
    Karageorgis, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S162 - S163
  • [15] Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM)
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Peters, K.
    Kirkpatrick, J.
    Herndon, J. E.
    Marcello, J.
    Bailey, L.
    Threatt, S.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [16] SAFETY AND EFFICACY OF TEMOZOLOMIDE TREATMENT WITH NEWLY DIAGNOSED GLIOBLASTOMA IN JAPAN: A MULTICENTER PHASE II CLINICAL STUDY
    Sugiyama, Kazuhiko
    Nishikawa, Ryo
    Takeshima, Hideo
    Nakamura, Hideo
    Aoki, Tomokazu
    Takahashi, Jun
    Takahash, Hideaki
    Saito, Akihiko
    Sawamura, Yutaka
    Kurisu, Kaoru
    Matsutani, Masao
    NEURO-ONCOLOGY, 2009, 11 (06) : 948 - 948
  • [17] Combination of Tumor Treating Fields (TTFields) with lomustine (CCNU) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)
    Lazaridis, L.
    Kebir, S.
    Weller, J.
    Tzaridis, T. -D
    Scheffler, B.
    Pierscianek, D.
    Kleinschnitz, C.
    Stuschke, M.
    Sure, U.
    Herrlinger, U.
    Schaefer, N.
    Glas, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S109 - S109
  • [18] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Lazaridis, Lazaros
    Schaefer, Niklas
    Kebir, Sied
    Weller, Johannes
    Tzaridis, Theophilos-Dimitrios
    Scheffler, Bjoern
    Pierscianek, Daniela
    Kleinschnitz, Christoph
    Stuschke, Martin
    Sure, Ulrich
    Herrlinger, Ulrich
    Glas, Martin
    NEURO-ONCOLOGY, 2018, 20 : 119 - 120
  • [19] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Lazaridis, L.
    Schaefer, N.
    Kebir, S.
    Weller, J.
    Tzaridis, T.
    Schaeffler, B.
    Pierscianek, D.
    Kleinschnitz, C.
    Stuschke, M.
    Sure, U.
    Herrlinger, U.
    Glas, M.
    NEURO-ONCOLOGY, 2018, 20 : 230 - 230
  • [20] PHASE I STUDY OF IBRUTINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Ahluwalia, Manmeet
    Patel, Neha
    Khosla, Atulya
    Rauf, Yasmeen
    Stevens, Glen
    Murphy, Erin
    Chao, Samuel
    Yu, Jennifer
    Suh, John
    Peereboom, David
    NEURO-ONCOLOGY, 2022, 24 : 60 - 60
12345